NASDAQ:ZEALZEALAND PHARMA/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ZEALAND PHARMA/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $35.85 +1.09 (+3.14 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$35.29Now: $35.86▼$35.8850-Day Range$32.09MA: $36.78▼$41.0052-Week Range$18.75Now: $35.86▼$44.60Volume2,549 shsAverage Volume7,211 shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/ABeta1.24 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH; and Alexion Pharmaceuticals, Inc. for the discovery and development of peptide therapies for complement-mediated diseases. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingZEALAND PHARMA/S has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.00, ZEALAND PHARMA/S has a potential upside of 11.6% from its current price of $35.86.Amount of Analyst CoverageZEALAND PHARMA/S has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesZEALAND PHARMA/S has received 279 “outperform” votes. (Add your “outperform” vote.)Underperform VotesZEALAND PHARMA/S has received 285 “underperform” votes. (Add your “underperform” vote.)Community SentimentZEALAND PHARMA/S has received 50.53% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ZEALAND PHARMA/S and other stocks. Vote “Outperform” if you believe ZEAL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldZEALAND PHARMA/S does not currently pay a dividend.Dividend GrowthZEALAND PHARMA/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ZEALAND PHARMA/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 6.38% of the stock of ZEALAND PHARMA/S is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ZEALAND PHARMA/S are expected to decrease in the coming year, from ($3.07) to ($3.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ZEALAND PHARMA/S is -13.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ZEALAND PHARMA/S is -13.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZEALAND PHARMA/S has a P/B Ratio of 6.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.98 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZEAL Previous Symbol CUSIPN/A CIK1674988 Webwww.zealandpharma.com Phone45-8877-3600Debt Debt-to-Equity Ratio0.08 Current Ratio7.30 Quick Ratio7.30Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.20 million Price / Sales229.76 Cash FlowN/A Price / Cash FlowN/A Book Value$5.85 per share Price / Book6.13Profitability EPS (Most Recent Fiscal Year)($2.54) Net Income$-85,670,000.00 Net Margins-1,157.20% Return on Equity-51.41% Return on Assets-40.71%Miscellaneous Employees149 Outstanding Shares39,730,000Market Cap$1.42 billion Next Earnings Date8/20/2020 (Estimated) OptionableNot Optionable NASDAQ:ZEAL Rates by TradingView Receive ZEAL News and Ratings via Email Sign-up to receive the latest news and ratings for ZEAL and its competitors with MarketBeat's FREE daily newsletter. ZEALAND PHARMA/S (NASDAQ:ZEAL) Frequently Asked Questions How has ZEALAND PHARMA/S's stock been impacted by COVID-19 (Coronavirus)? ZEALAND PHARMA/S's stock was trading at $28.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZEAL shares have increased by 27.6% and is now trading at $35.8550. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ZEALAND PHARMA/S? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ZEALAND PHARMA/S. When is ZEALAND PHARMA/S's next earnings date? ZEALAND PHARMA/S is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for ZEALAND PHARMA/S. How were ZEALAND PHARMA/S's earnings last quarter? ZEALAND PHARMA/S (NASDAQ:ZEAL) announced its earnings results on Thursday, May, 14th. The company reported ($4.98) EPS for the quarter, missing the consensus estimate of ($0.63) by $4.35. The business earned $1.83 million during the quarter, compared to analysts' expectations of $5.13 million. ZEALAND PHARMA/S had a negative return on equity of 51.41% and a negative net margin of 1,157.20%. View ZEALAND PHARMA/S's earnings history. What price target have analysts set for ZEAL? 5 Wall Street analysts have issued twelve-month price objectives for ZEALAND PHARMA/S's shares. Their forecasts range from $37.00 to $42.00. On average, they expect ZEALAND PHARMA/S's stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 11.6% from the stock's current price. View analysts' price targets for ZEALAND PHARMA/S. Has ZEALAND PHARMA/S been receiving favorable news coverage? Headlines about ZEAL stock have been trending negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. ZEALAND PHARMA/S earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days. View the latest news about ZEALAND PHARMA/S. Who are some of ZEALAND PHARMA/S's key competitors? Some companies that are related to ZEALAND PHARMA/S include United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), Myokardia (MYOK), Blueprint Medicines (BPMC), Nektar Therapeutics (NKTR), Biohaven Pharmaceutical (BHVN), Global Blood Therapeutics (GBT), Evotec (EVTCY), Amicus Therapeutics (FOLD) and GW Pharmaceuticals PLC- (GWPH). View all competitors. What other stocks do shareholders of ZEALAND PHARMA/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other ZEALAND PHARMA/S investors own include GALAPAGOS NV/S (GLPG), Eyepoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Portola Pharmaceuticals (PTLA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Zymeworks (ZYME), AbbVie (ABBV), Protalix Biotherapeutics (PLX) and SCYNEXIS (SCYX). Who are ZEALAND PHARMA/S's key executives? ZEALAND PHARMA/S's management team includes the following people: Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Director (Age 66)Dr. Emmanuel Dulac Ph.D., PharmD, MBA, CEO & Pres (Age 49)Mr. Ivan Mourits Møller, Interim CFO and Sr. VP of Technical Devel. & Operations (Age 47)Dr. Andrew Parker, Exec. VP & Chief Science Officer (Age 54)Lani Pollworth Morvan, Investor Relations & Communications Officer When did ZEALAND PHARMA/S IPO? (ZEAL) raised $75 million in an initial public offering on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. What is ZEALAND PHARMA/S's stock symbol? ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL." How do I buy shares of ZEALAND PHARMA/S? Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ZEALAND PHARMA/S's stock price today? One share of ZEAL stock can currently be purchased for approximately $35.86. How big of a company is ZEALAND PHARMA/S? ZEALAND PHARMA/S has a market capitalization of $1.42 billion and generates $6.20 million in revenue each year. The company earns $-85,670,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. ZEALAND PHARMA/S employs 149 workers across the globe. What is ZEALAND PHARMA/S's official website? The official website for ZEALAND PHARMA/S is www.zealandpharma.com. How can I contact ZEALAND PHARMA/S? ZEALAND PHARMA/S's mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The company can be reached via phone at 45-8877-3600 or via email at [email protected] This page was last updated on 7/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
